Sigrid Henke-Fahle, M.D.

Affiliations: 
Eye Clinic Eberhard Karls Universität Tübingen, Tübingen, Baden-Württemberg, Germany 
Google:
"Sigrid Henke-Fahle"
Mean distance: 106866
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Suesskind D, Gauss S, Faust UE, et al. (2013) Characterisation of novel uveal melanoma cell lines under serum-free conditions. Graefe's Archive For Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv FüR Klinische Und Experimentelle Ophthalmologie. 251: 2063-70
Schramm C, Spitzer MS, Henke-Fahle S, et al. (2012) The cross-linked biopolymer hyaluronic acid as an artificial vitreous substitute. Investigative Ophthalmology & Visual Science. 53: 613-21
Suesskind D, Schatz A, Schnichels S, et al. (2012) GDF-15: a novel serum marker for metastases in uveal melanoma patients. Graefe's Archive For Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv FüR Klinische Und Experimentelle Ophthalmologie. 250: 887-95
Thaler S, Fiedorowicz M, Choragiewicz TJ, et al. (2010) Toxicity testing of the VEGF inhibitors bevacizumab, ranibizumab and pegaptanib in rats both with and without prior retinal ganglion cell damage. Acta Ophthalmologica. 88: e170-6
Jaissle GB, Ulmer A, Henke-Fahle S, et al. (2009) [Intraocular bevacizumab as palliative therapy in melanoma-metastasis-associated rubeotic secondary glaucoma]. Klinische MonatsbläTter FüR Augenheilkunde. 226: 70-2
Tura A, Schuettauf F, Monnier PP, et al. (2009) Efficacy of Rho-kinase inhibition in promoting cell survival and reducing reactive gliosis in the rodent retina. Investigative Ophthalmology & Visual Science. 50: 452-61
Zhu Q, Ziemssen F, Henke-Fahle S, et al. (2008) Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology. 115: 1750-5, 1755.e1
Jaissle GB, Ulmer A, Henke-Fahle S, et al. (2008) Suppression of melanoma-associated neoangiogenesis by bevacizumab. Archives of Dermatology. 144: 525-7
Yoeruek E, Ziemssen F, Henke-Fahle S, et al. (2008) Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmologica. 86: 322-8
Julien S, Schnichels S, Teng H, et al. (2008) Purkinje cell survival in organotypic cultures: implication of Rho and its downstream effector ROCK. Journal of Neuroscience Research. 86: 531-6
See more...